Accretive Health (NYSE:AH)
Advanced Practice Strategies
AliphCom (dba Jawbone)
Bardy Diagnostics, Inc.
Cofactor Genomics, Inc.
Comprehensiive Pharmacy Services
CSA Medical, Inc.
EBR Systems, Inc.
Haven Behavioral Healthcare
Imperative Care, Inc.
Ingenious Med, Inc.
Intelligent Medical Objects, Inc.
Millennium Pharmacy Systems
Ob Hospitalist Group
Ocular Therapeutix (NASD:OCUL)
Solstas Lab Partners
Sonoma Orthopedic Products
United Surgical Partners International
ZONARE Medical Systems
Accretive Health (NYSE:AH)www.accretivehealth.com
Advanced Practice Strategieswww.aps-web.com
AliphCom (dba Jawbone)www.bodymedia.com
Bardy Diagnostics, Inc.www.bardydx.com
Bardy Diagnostics, Inc. ("BardyDx") was founded to address a longstanding complaint in cardiac arrhythmia monitoring that current monitors are large, bulky, uncomfortable and frequently record noisy QRS signals. BardyDx has responded to this complaint by providing a solution Ã¢â‚¬â€œ the Carnation Ambulatory Monitor, a non-invasive P-wave centricÃ¢â€Å¾Â¢ ambulatory cardiac monitor and arrhythmia detection device that generates superior clinical data, improves patient compliance and fits within varied hospital and cardiology workflows and reimbursement concern.
Cofactor Genomics, Inc.https://cofactorgenomics.com/
Cofactor Genomics uses RNA to help researchers and clinicians understand, diagnose, and predict drug response for the 95% of disease that canâ€™t be assessed. Cofactor has built a proprietary platform capable of overcoming the chemical and computational challenges of performing complex RNA fingerprint analysis on clinical-grade human samples and is in the process of commercializing a suite of clinical diagnostic assays targeting oncologic, immunologic, and neurodegenerative diseases.
Comprehensiive Pharmacy Serviceswww.cpspharm.com
CSA Medical, Inc.www.csamedical.com
EBR Systems, Inc.http://www.ebrsystemsinc.com/
Haven Behavioral Healthcarewww.havenbehavioral.com
HealthMyne’s proprietary algorithms automate the extraction of quantitative imaging metrics at the Point-of-Read, greatly reducing inter- and intra-reader variability and making evidence-based metrics available at the Point-of-Care. These volumetric measurements are combined with clinical information from the EMR, PACS, Radiation Therapy and other systems to drive transformed CDS workflow modules (Cancer Screening, Tumor Board Management, Clinical Trials/Therapy Response Assessment, Incidental Findings, Thoracic Specialty, others), actionable quantitative reports, and an integrated imaging and clinical patient-centric dashboard to impact daily patient management decisions.
Imperative Care, Inc.
Ingenious Med, Inc.www.ingeniousmed.com
Instylla is a development-stage company creating a new standard in embolization therapy for use in interventional radiology and oncology that will allow physicians to perform a variety of procedures with shorter procedure times, higher technical confidence and potentially improved efficacy.